Improving outcomes in state AIDS drug assistance programs.

Area of Science:

• Public Health
• HIV/AIDS Medicine
• Health Services Research

Background:

• State AIDS Drug Assistance Programs (ADAPs) are crucial for providing antiretroviral medications to uninsured HIV patients.
• Resource limitations in ADAPs challenge their ability to meet the growing demand for services.

Purpose of the Study:

• To identify ADAP eligibility criteria that effectively minimize patient morbidity and mortality while managing program costs.
• To compare the outcomes of different ADAP eligibility policies under resource constraints.

Main Methods:

• Discrete Event Simulation was employed to model HIV patient progression and ADAP utilization.
• Key outcomes assessed included 5-year mortality, incidence of opportunistic infections or death, and time to antiretroviral therapy (ART) initiation.
• Two eligibility policies were compared: current first-come, first-served (FCFS) versus CD4 count-prioritized access.

Main Results:

• Prioritizing patients with CD4 counts ≤250/microL demonstrated lower 5-year mortality (2.77 vs. 3.27 deaths per 1,000 person-months) and reduced incidence of opportunistic infections or death (5.55 vs. 6.98 events per 1,000 person-months) compared to FCFS.
• CD4-based prioritization accelerated ART initiation for patients with CD4 counts ≤200/microL.
• Sensitivity analyses confirmed that CD4-based eligibility consistently yielded better health outcomes than FCFS.

Conclusions:

• Under conditions of limited resources, ADAPs can enhance patient outcomes by prioritizing individuals with lower CD4 counts for antiretroviral therapy.
• This prioritization strategy is effective in mitigating morbidity and mortality among vulnerable HIV-infected populations.